Loading
PDCD4 (Programmed cell death protein 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.
Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Paclitaxel.
In plain words · PDCD4 (Programmed cell death protein 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.
PDCD4 (Programmed cell death protein 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.
Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G.
No product in this corpus aims at PDCD4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PDCD4: RNA tissue enhanced (pancreas 477 nTPM); high antibody staining in 32 normal tissues; highest cancer staining ovarian cancer (12 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PDCD4 tissue; Open Targets ENSG00000150593 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Matsuhashi et al, Res. Commun. Biochem. Cell Mol. Biol, 1997, "Isolation of a novel gene from a human cell line with Pr-28 MAb which recognizes a nuclear antigen involved in the cell cycle". Source.
Sources: HGNC HGNC:8763 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q53EL6 (protein name, function text, keywords and locations (REST API)); CIViC gene PDCD4 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Cancer (GraphQL API, CC0))
Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. May play a role in apoptosis. Location: Nucleus; Cytoplasm (UniProt). Locus 10q25.2 (HGNC).
RNA: tissue enhanced (pancreas 477 nTPM), detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Cerebral cortex, Heart muscle, Kidney, Lung, Skeletal muscle, Smooth muscle.
Medium only: pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PDCD4" OR ABSTRACT:"PDCD4" OR TITLE:"programmed cell death 4" OR ABSTRACT:"programmed cell death 4" OR TITLE:"Programmed cell death protein 4" OR ABSTRACT:"Programmed cell death protein 4" OR TITLE:"H731" OR ABSTRACT:"H731") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDCD4, not a curated reading list.